NEW YORK, Aug. 17, 2018 /PRNewswire/ -- Chardan, a global
investment bank, announced today that the firm acted as sole
placement agent in Krystal Biotech, Inc.'s (NASDAQ: KRYS)
securities purchase agreement with Frazier Healthcare Partners for
the private placement of 625,000 shares at $16 per share. The private placement will yield
gross proceeds of $10 million.
"We're pleased to have partnered with Krystal Biotech to support
the firm's efforts to continue its impressive research in
dermatological diseases," said Jonas
Grossman, President of Chardan. "Our experience in the space
allowed us to find the capital needed to support this growth and
we're looking forward to working with the team at Krystal to
support future advancements."
Chardan has participated in advisory and capital raising
transactions totaling more than $2
billion in 2018.
About Chardan Capital Markets
Chardan provides a full suite of Global Investment Banking
services designed for emerging growth companies. Our full range of
services includes capital raising, merger and acquisition advisory,
strategic advisory, equity research, institutional trading and
market making. Headquartered in New York
City, Chardan is a registered broker-dealer with the U.S.
Securities and Exchange Commission and is a member of the
following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.
To learn more about Chardan, visit www.chardan.com
Media Contact:
Emily
Levine, Chardan Capital Markets
elevine@chardan.com
(646) 465-9018
Tom Rozycki, Prosek Partners
trozycki@prosek.com
(646) 503-5657
View original
content:http://www.prnewswire.com/news-releases/chardan-capital-markets-acts-as-sole-placement-agent-in-10-million-securities-purchase-300698844.html
SOURCE Chardan Capital Markets, LLC